Candel Therapeutics Competitors and Similar CompaniesClear all

ESSA Pharma's competitors and similar companies include Signpath Pharma, Trethera and Allogene Therapeutics.
ESSA Pharma
ESSA Pharma
ESSA Pharma is a pharmaceutical company focused on developing therapies for the treatment of prostate cancer.
Signpath Pharma
Signpath Pharma
SignPath Pharma is a biotechnology company that develops products to treat cancer and mitigate drug-induced cardiac arrhythmia.
Trethera
Trethera
Trethera is a preclinical-stage biopharmaceutical company developing cancer treatments.
Allogene Therapeutics
Allogene Therapeutics
Allogene Therapeutics is a clinical-stage biotechnology company developing allogeneic chimeric antigen receptor T cell (AlloCAR T) products for cancer.
Founding Date
Founding Date
2009
Founding Date
2006
Founding Date
2013
Founding Date
2018
Type
Type
Public
Type
Private
Type
Private
Type
Public
Tags
Locations
Locations
Vancouver, CA HQ
Houston, US
South San Francisco, US
Locations
Sandy, US HQ
Locations
Los Angeles, US HQ
Locations
South San Francisco, US HQ
Employees
Employees
50
Employees
10
Employees
6
Employees
35917% increase
Valuation ($)
Valuation ($)
257.8 m
Valuation ($)
N/A
Valuation ($)
N/A
Valuation ($)
558.3 m

Financial

Net income
Net income
($26.6m) (FY, 2023)
Net income
N/A
Net income
N/A
Net income
($332.6m) (FY, 2022)

Funding

Total funding raised
Total funding raised
$ 74.1m
Total funding raised
$ 5.3m
Total funding raised
$ 7.4m
Total funding raised
$ 532m
For sources of this data, please see the company profile

View Company Profiles

Signpath Pharma
HQ
Sandy, US
Employees
10

SignPath Pharma is a biotechnology company that develops products to treat cancer and mitigate drug-induced cardiac arrhythmia.

View company
Trethera
HQ
Los Angeles, US
Employees
6

Trethera is a preclinical-stage biopharmaceutical company developing cancer treatments.

View company
Allogene Therapeutics
HQ
South San Francisco, US
Employees
359↑ 17% increase

Allogene Therapeutics is a clinical-stage biotechnology company developing allogeneic chimeric antigen receptor T cell (AlloCAR T) products for cancer.

View company